Table 1 A summary of the demographic, CNS collection, and pharmacological history data (mean±s.e.m.) for cases used in this study

From: Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia

Diagnoses

Age (years)

Sex

DI (years)

Suicide

PMI (h)

pH

FRADD

LEAP

Anti-Ch

Benz

RIN

           

BA 8

BA 9

BA 44

Controls

49±3

24M/6F

N/A

0Y/20N

44±3

6.36±0.03

N/A

N/A

N/A

N/A

6.0±0.2

8.9±0.1

7.8±0.23

Schizophrenia

48±3

25M/5F

22±2.8

8Y/22N

41±2.3

6.26±0.04

601±99

12.9±3.1

13Y/17N

12Y/18N

6.0±0.29

8.8±0.1

7.8±0.16

P

0.91

1.00

  

0.41

0.03

    

0.92

0.52

0.74

MRDS

48±4.1

13M/2F

22±4.1

4Y/11N

39±2.7

6.30±0.04

642±154

15±5.0

7Y/8N

7Y/8N

5.9±0.42

8.7±0.16

7.8±0.25

Non-MRDS

49±4.5

12M/3F

22±4.0

4Y/11N

42±4.0

6.23±0.06

553±124

11±3.8

6Y/9N

5Y/10N

6.2±0.40

8.8±0.1

7.9±0.2

d.f.

2,57

   

2,57

2,57

    

2,57

2,57

2,34

P

0.99

0.85

0.94

1.00

0.67

0.06

0.66

0.48

1.00

0.71

0.80

0.78

0.94

Mood disorders

             

Controls

62±4.1

6M/4F

N/A

0Y/9N

47±5.4

6.29±0.08

N/A

N/A

N/A

N/A

 

6.2±0.5

 

MDD

62±5.0

6M/4F

17.60±3.4

8Y/2N

39±5.0

6.58±0.06

305±305

1.5±1.5

10N/0Y

2Y/8N

 

6.7±0.27

 

BD

60±4.0

6M/4F

20.30±4.1

3Y/7N

31±4.5

6.35±0.06

158±51

0.75±0.37

8N/2Y

4Y/6N

 

5.7±0.52

 

d.f.

2,27

   

2,27

2,27

     

2,26

 

P

0.88

1.00

0.62

0.07

0.08

<0.0001

0.5

0.62

0.47

0.62

 

0.30

 

Cont versus MDD

     

0.001

       

Cont versus BD

     

NS

       

MDD versus BD

     

0.001

       
  1. Abbreviations: Anti-Ch, treated with anticholinergic drugs; BD, bipolar disorders; Benz, treated with benzodiazepines; DI, duration of illness; F, female; FRADD, final recorded antipsychotic drug dose converted to chlorpromazine equivalents; LEAP, lifetime exposure to antipsychotic drugs converted to chlorpromazine equivalents×10−3; M, male; MDD, Major Depressive Disorders; MRDS, Muscarinic Deficit Schizophrenia; N, No; N/A, not applicable; Non-MRDS, subjects with schizophrenia without a deficit in cortical muscarinic M1 receptors; NS, non-significant; PMI, postmortem interval; RIN, RNA integratory number; Y, yes.
  2. Bolded entries show significant variations with diagnoses.
Back to article page